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Background: This study was performed to establish age-related serum reference intervals for procollagen type
I N-propeptide (P1NP) and type I collagen C-telopeptide (CTx) in the Australian population.
Methods: Fasting sera from 1143 males (mean age 60 years; range 20–97 years) and 1246 females (mean age
53 years; range 20–93 years) who participated in the Geelong Osteoporosis Study were analysed for CTx and
P1NP using the automated Roche Modular Analytics E170 analyser.
Results: Optimal age-related reference intervals were based on the central 90% of the distribution. The male
CTx reference interval was divided into three age groups. For men aged 25 to 40 years, the interval was 170–
600 ng/L; 40 to 60 years, the interval was 130–600 ng/L; and for men aged greater 60 years the interval was
100–600 ng/L.
For P1NP themale reference interval was 15–80 μg/L for men aged between 25 to 70 years. In men greater than
70 years of age values were higher possibly due to increased bone turnover.
High values are frequently seen for both CTx and P1NP in males aged younger than 25 years. This is probably
due to bone growth that is not completely finalised.
The female CTx reference interval was divided into four age groups. For women aged less than 30 years, the inter-
val was 150–800 ng/L; 30–39 years, the interval was 100–700 ng/L; 40–49 years, the intervalwas 100–600 ng/L;
and for women aged 50 years or more the interval was 100–700 ng/L.
The female P1NP reference interval was divided into four age groups. For women aged less than 30 years, the
interval was 25–90 μg/L; 30–39 years, the interval was 15–80 μg/L; 40–49 years, the interval was 15–60 μg/L;
and for women aged 50–69 years the interval was 15–75 μg/L. In women greater than 70 years of age values
were higher possibly due to increased bone turnover.
Conclusion: Values obtained from this large study provide sound age-related reference intervals for serum P1NP
and CTx values in the Australian population.© 2013 Elsevier Inc. All rights reserved.Introduction
Osteoporosis is a systemic skeletal disorder characterised by a
reduced bone mass and deterioration of osseous microarchitecture,
resulting in decreased bone strength and increased risk of fragility
fractures, particularly of the spine, hip and wrist.
Osteoporosis currently affects approximately 10% of the Australian
population and it is estimated that approximately 60% of women andClinical Biochemistry Unit, PO
3781.
s), M.Black@alfred.org.au
rwonhealth.org.au (J.A. Pasco),
erh@alfred.org.au
rights reserved.30% of men over the age of 60 will suffer from an osteoporotic frac-
ture [1].
Monitoring acute changes in bone is difficult with the static infor-
mation given by bone mass evaluation, usually carried out by means
of bone mineral density (BMD) measurement. The annual changes
in BMD, associated with age-related bone loss and therapeutic inter-
ventions are small and similar to the measurement error of the tech-
nique. Consequently the popularity of biochemical bone turnover
markers (BTM) has grown. BTM have been shown in some studies
to be significantly associated with subsequent bone loss [2,3]. In addi-
tion, an association has been found, though not consistently, between
bone resorption markers and fracture risk [4]. Bone formation
markers are generally not associated with fracture risk, except bone
alkaline phosphatase, which has predicted fragility fractures in some
cohorts [4–6].
Table 1
Characteristics of the male cohort.
Age
group
(years)
n CTx (ng/mL) P1NP
(μg/L)
Weight
(kg)
Height
(cm)
BMI
(kg/m2)
20–29 85 528 (453–676) 61 (45–78) 81.5 ± 19.2 179.9 ± 6.7 25 ± 5
30–39 114 361 (276–466) 41 (34–51) 84.9 ± 16.6 178.6 ± 7.3 27 ± 4
40–49 136 311 (228–399) 37 (29–47) 84.7 ± 12.7 176.5 ± 7.0 27 ± 4
50–59 196 303 (227–412) 36 (28–44) 86.7 ± 14.9 175.6 ± 6.2 28 ± 4
60–69 184 284 (209–398) 33 (24–43) 85.5 ± 13.7 173.8 ± 6.5 28 ± 4
70–79 230 315 (216–426) 35 (26–48) 82.0 ± 13.3 172.0 ± 6.5 28 ± 4
80+ 198 339 (231–511) 37 (26–54) 75.8 ± 11.9 170.0 ± 6.6 26 ± 4
Values are mean ± standard deviation or median (inter-quartile range) as appropriate.
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C-telopeptide (CTx) have been identified as the most promising
BTM by the Joint IOF (International Osteoporosis Foundation)–IFCC
(International Federation of Clinical Chemistry and Laboratory
Medicine) Bone Marker Standards Working Group [7].
P1NP is a propeptide that is released during the processing of type
I procollagen into collagen. It is regarded as a bone formation marker,
is synthesised by osteoblasts and correlates with histomorphometric
parameters of bone formation [8,9]. By contrast, CTx arises from
collagen degradation and correlates with histomorphometric param-
eters of bone resorption [8,9].
Reference intervals for women, particularly post-menopausal
have been widely published [10–15]. However there is an absence
of this type of data in men. The aim of this study was to establish
age-related serum reference intervals for P1NP and CTx values in the
Australian population as determined by automated methods.
Materials and methods
Study population
The specimens used in this study were obtained from an age-
stratified random sample of participants from the Geelong
Osteoporosis Study. This study consists of a large, strictly random,
community dwelling population-based cohort. All subjects provided
written consent and were recruited from an area surrounding
Geelong, called the Barwon Statistical Division. This region is compara-
ble to the Australian population in age distribution and socio-economic
indicators consisting of urban and rural communities. Subjects were not
screened for bone ormetabolic diseases, nor were they screened for use
of drugs that affect bone turnover. Details of recruitment and exclusion
criteria of the study sample have been published elsewhere [16].
The male samples (n = 1143; mean age 60 years; range 20–
97 years) were collected from 2003–2008. There were originally
1540 male subjects however 397 were excluded as no fasting serum
sample was available. Characteristics of the male cohort are shown
in Table 1.
The female samples used in this study (n = 1246; mean age
53 years; range 20–93 years) were collected from 1993–1997. ThereTable 2
Characteristics of the female cohort.
Age group (years) n CTx (ng/mL) P1NP (μg/L) Weight (kg) He
20–29 166 379 (291–554) 45 (35–61) 65.7 ± 13.3 163
30–39 215 264 (184–384) 31 (24–46) 69.2 ± 16.3 163
40–49 209 246 (160–341) 29 (23–37) 71.8 ± 15.4 162
50–59 176 331 (196–479) 34 (24–51) 71.3 ± 13.6 161
60–69 176 343 (204–484) 38 (26–48) 71.7 ± 14.3 159
70–79 151 407 (281–596) 39 (28–53) 66.7 ± 12.9 156
80+ 153 507 (372–630) 49 (36–63) 62.1 ± 10.8 155
Values are mean ± standard deviation, median (inter-quartile range) or proportions.were originally 1494 female subjects however 248 were excluded as
no fasting serum sample was available. Characteristics of the female
cohort are shown in Table 2.
Serum samples were collected from both cohorts after an over-
night fast between 07:30 and 11:45. They were then centrifuged for
10 min at 3000 g approximately 1–3 h after collection. The samples
were then aliquoted and stored frozen at −80 °C until analysis.
Ethics approval was received from the Barwon Health Human
Research Ethics Committee.
Biochemical markers
All samples were analysed in 2008 for CTx and P1NP using the au-
tomated Roche Modular Analytics E170 analyser (Roche Diagnostics,
Mannheim, Germany).
Both biochemical markers were measured at the same time using
a single lot of each assay reagent, according to the manufacturer's
protocol and following the laboratory quality control procedures.
The serum CTx limit of detection was 10 ng/L with inter-assay
coefficient of variations (CVs) of 6.5% at 361 ng/L, 3.8% at 816 ng/L
and 3.4% at 3304 ng/L (n = 10).
Serum P1NP inter-assay CVs were 4.9% at 73 μg/L, 2.6% at 392 μg/L,
and 2.1% at 768 μg/L (n = 10) with a limit of detection of 5 μg/L.
Statistical analysis
Statistical analysis of data was performed using SAS software ver-
sion 9.1 (SAS Institute Inc, Cary, NC, USA). CTx and P1NP were initially
assessed for normality and found to have distributions that were
skewed to the right. Thus these variables underwent logarithmic
transformation before statistical analyses.
The geometric mean (95% confidence interval), as well as the
2.5th, 5th, 95th and 97.5th percentiles were calculated for partici-
pants separated into age groups by decades. Optimal age-related
reference intervals were based on the central 90% of the distribution.
Characteristics of female and male cohorts were summarised using
mean ± standard deviation, median (inter-quartile range) or propor-
tions as appropriate.
Results
Male cohort
In the male cohort the median serum P1NP and CTx values were
37 μg/L (IQR 27–49 μg/L) and 328 ng/L (IQR 235–459 ng/L) respec-
tively. Neither of the BTM were distributed normally, but skewed to-
wards the right. After log-transformation, data for both variables
showed a Gaussian distribution. The ranges of distributions were
from 5 to 726 μg/L for P1NP and 18 to 1810 ng/L for CTx.
There was no seasonal variation seen.
When the data were plotted against age by decade a U-shaped rela-
tionship was seen for CTx (Fig. 1). CTx declined until ages 40–50 yearsight (cm) BMI (kg/m2) Post-menopausal (%) Oral contraceptive use (%)
.8 ± 5.8 24 ± 5 0 53
.3 ± 6.1 26 ± 6 2 28
.8 ± 6.0 27 ± 6 20 12
.1 ± 5.9 27 ± 5 82 2
.5 ± 6.1 28 ± 6 100 0
.8 ± 5.8 27 ± 5 100 0
.0 ± 6.0 26 ± 4 100 0
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Fig. 1. Age-related distribution of CTx values in the male cohort.
Table 3
Suggested male and female reference intervals for CTx and P1NP.
Gender Age group
(years)
Suggested CTx reference
interval (ng/L)
Suggested P1NP reference
interval (μg/L)
Male 25–40 170–600
40–60 130–600
>60 100–600
25–70 15–80
Female b30 150–800 25–90
30–39 100–700 15–80
40–49 100–600 15–60
>50 100–700
50–69 15–75
273N. Jenkins et al. / Bone 55 (2013) 271–276and then gradually increased until age 70 years, afterwhich it increased
sharply.
P1NP values also showed a similar U-shaped distribution (Fig. 2).
P1NP was relatively higher for men in their 20s and then fell and
remained stable until age 80 years, after which the values increased
sharply.
Within the 20–29 year age group CTx and P1NP values decreased
with increasing age (data not shown).
Reference intervals were determined using the central 90% of the
distribution. These are shown in Table 3.
If we were to base the reference intervals on the 2.5th and 97.5th
percentile the male CTx reference interval would have been divided
into two age groups. For men aged 25 to 40 years, the interval
would be 150–800 ng/L; and for men aged greater than 40 years
the range would be 100–700 ng/L.
The P1NP male reference interval would have been 10–80 μg/L for
men aged between 25 and 70 years.
Female cohort
The female cohort had a median serum P1NP value of 37 μg/L (IQR
26–51 μg/L) and a median CTx value of 338 ng/L (IQR 212–499 ng/L).
The values were skewed towards the right and required log-
transformation to achieve a Gaussian distribution. The distribution of
these results ranged from 5 to 495 μg/L for P1NP and 10 to 2863 ng/L
for CTx.0
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Fig. 2. Age-related distribution of P1NP values in the male cohort.When we investigated the bone resorption marker for seasonal
variation, we found lower CTx values in autumn compared to higher
values in spring. By contrast, the bone formation marker (P1NP)
values showed no seasonal variation.
CTx initially decreased between the ages of 20–49 years after
which the values started to rise (Fig. 3). P1NP showed a similar pat-
tern where values decreased between the ages of 20–49 years and
then started to increase (Fig. 4).
When separated according to menopausal status, the pre-
menopausal women had a median serum P1NP value of 33 μg/L
(IQR 25–48 μg/L) and a median CTx value of 289 ng/L (IQR 191–
406 ng/L). The post-menopausal group had a serum P1NP value of
40 μg/L (IQR 28–53 μg/L) and a median CTx value of 399 ng/L (IQR
241–546 ng/L).
The reference intervals were determined using the central 90%
of the distribution. These are shown in Table 3.
If we were to base the reference intervals on the 2.5th and 97.5th
percentile the female CTx reference interval would have been divided
into four age groups. For women aged less than 30 years, the interval
would be 100–900 ng/L; 30–39 years, the interval would be 50–
900 ng/L; 40–49 years, the interval would be 50–700 ng/L; and for
women aged 50 years or more the interval would be 50–900 ng/L.
The female P1NP reference interval would have also been divided
into four age groups. For women aged less than 30 years, the interval
would be 20–100 μg/L; 30–39 years, the interval would be 10–
100 μg/L; 40–49 years, the interval would be 10–70 μg/L; and for
women aged 50–69 years the interval would be 10–85 μg/L.
Discussion
As new automated techniques to determine BTM are becoming
increasingly common, it is essential that relevant normal reference
intervals be established. Typically assays do not completely agree on0
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Fig. 3. Age-related distribution of CTx values in the female cohort.
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274 N. Jenkins et al. / Bone 55 (2013) 271–276different platforms and differences of up to 15–20% have been
seen. We have studied the serum levels of P1NP and CTx determined
by the Elecsys E170 analyser (Roche Diagnostics) in a large well
characterised cohort of 1143 Australian men and 1246 Australian
women who were randomly selected from an electoral register and
are thus representative of the underlying population.
Literature shows that P1NP values assessed by automated
methods appear to be similar in Caucasian men in different countries
whereas CTx values appear to differ across different populations
(Table 4). In this study, the male CTx reference interval was divided
into three age groups. Whilst the upper end of the reference interval
stayed stable, the lower end decreased with age. These findings are
important as CTx values less than 150–200 ng/L have been used to
identify patients that need to cease bisphosphonate use due to the
risk for developing osteonecrosis of the jaw after tooth extraction
[19]. Based on our data a part of the “normal” population will have
CTx values below 200 ng/L.
The male 20–29 year age group was further analysed and it could
be seen that CTx and P1NP values decrease with increasing age
during this decade. This is likely the result of consolidation of bone
formation.
Bone histomorphometry studies have shown that bone resorption,
bone formation and cancellous bone volume (BV/TV) decrease with
age [20,21]. Generally BV/TV increases progressively, albeit slightly
until the third decade of life, and decreases thereafter. In males
there is a continuous loss of bone volume.
Wishart et al. found that BTM in men show their lowest levels
between 50–60 years [22]. Similarly we find a slow decrease in medi-
an CTx levels until they stabilise after age 40–49 years.
In elderly men, age-related increase, stability or decrease of bone
resorption markers have been described [22–24]. Bone resorption
does increase in elderly men, but this increase is slight, progressive
and starts after the age of 60. This increase was seen in our study
but is sometimes not detected in cohorts containing few men aged
60 and over.
Bone formation markers such as P1NP remain roughly stable
between 40 and 60 years, independent of the marker studied. Over
60 years, they remain stable or increase slightly in cohorts that
include very old men [23]. This suggests that, in elderly men, slightly
increased bone resorption is not matched by a parallel increase in
bone formation and this imbalance might be expected to result in a
net bone loss.
As in men, literature shows that P1NP values assessed by automat-
ed methods appear to be alike in Caucasian women in different coun-
tries whereas CTx values vary across different populations (Table 5).
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275N. Jenkins et al. / Bone 55 (2013) 271–276Among females, bone histomorphometry studies have shown
that there is a trend toward reduction in BV/TV after the age of 50,
probably corresponding to the onset of menopause [20]. In women,
mineral apposition rate, wall thickness and osteoid thickness also
decline significantly with age [25]. As a novel finding we observed
that bone resorption markers decrease continuously after the second
decade of life until menopause, when bone turnover increases.
In our study P1NPwas not significantly different between pre- and
post-menopausal women.
Previously, menopause has been shown to be associated with an
acceleration in bone turnover, which is paralleled by a 50–100%
increase in both bone formation and bone resorption markers [26–28]
and consistent with the higher CTx values in post-menopausal women
compared with pre-menopausal women we found. In addition, bone
turnover continues to increase even during late menopause [29]. In this
study we find that older post-menopausal women (over 70 years) have
evidence of greater bone turnover as shown by the higher values of the
central 90% of the CTx and P1NP distributions comparedwith the decade
before. However, in this study we cannot exclude that the increased
serum CTx values we saw in elderly post-menopausal women was not
the result of decreased clearance as we did not measure renal function.
There is no simple explanation for the differences seen in CTx
reference intervals between studies whilst the P1NP reference inter-
vals agree. It is possible that bone resorption markers may be more
influenced by the particular characteristics and exposures of the par-
ticipants. Some of these differences could be accounted for by the
particular characteristics of the participants included in each study
such as age, weight, smoking habits, and physical activity.
The significant intra-individual and inter-assay variability of BTM rep-
resents a significant problem in their clinical application. Variability of
collection as well as diurnal variability have been described and lead to
wider reference intervals and less diagnostic certainty. It is known that
circadian variation is greater for bone resorption than bone formation.
For example serum CTx exhibits a circadian rhythm with an amplitude
of 80% of the 24 hour mean [30]. The amplitude of the variation of
bone formationmarkers ranges from 5% to 30% [31,32]. Food intake, hor-
monal changes, and renal function are also other important interfering
factors.
In this study, the samples were collected throughout the year
however in the male cohort the CTx and P1NP values did not show
seasonal variation. There was no seasonal variation in P1NP values
in women. Conversely the CTx and 25-hydroxyvitamin D3 data did
show seasonal variation as previously reported [33]. In the female co-
hort 25-hydroxyvitamin D3 levels decreased in winter whilst the CTx
values increased. The observed acceleration of bone turnover during
winter may at least in part be due to subclinical vitamin D deficiency
and secondary hyperparathyroidism. In studies that have exhibited a
significant seasonal variation in BTM, bone turnover tends to be lower
in summer than in winter and is related to seasonal changes in the
vitamin D-Parathyroid Hormone (PTH) axis [34]. It has also been
suggested that lower physical outdoor activities in winter may lead
to a net increase in bone resorption [35]. Other studies have shown
no wintertime increase in bone turnover despite a significant season-
al decrease in vitamin D levels [36,37].
The strengths of this study include the large sample size, and that
the participants were well characterised and representative of the
Australian population. All the samples were obtained at the same
time of day in a fasting state so that factors leading to biological
variability could be minimised.
However, this study has some limitations. One source of potential
error relates to the age of the samples. When assayed the specimens
from the female cohort were up to 15 years old whilst the male
cohort specimens were up to 5 years old. The serum samples used
were stored at −80 °C and did not undergo multiple freeze–thaw
cycles. Studies have shown that CTx is stable for at least 3 years in
serum samples frozen at or below −20 °C [38–40]. Others have
276 N. Jenkins et al. / Bone 55 (2013) 271–276demonstrated that P1NP is stable in serum when stored frozen for at
least 12 months at −80 °C [39,41].
As we did not measure PTH we were unable to exclude subjects
with abnormal PTH values and some may have been included in
this study. However by excluding such subjects results would then
not be able to be extrapolated to the general population. Caucasian
participants comprised >99% of subjects and thus, this data cannot
be extrapolated to other ethnicities. We recommend that reference
intervals be established for different ethnic groups.
Conclusion
In this study we report reference intervals for two BTM from a well
characterised population of Australian men and women spanning a
wide range of ages, using an automated technique. For serum P1NP
these values were similar to those previously described.
In women serum CTx levels were similar to those from studies
using pre-menopausal women but quite different from those focus-
sing on post-menopausal women.
The male serum CTx data was different to those previously
reported.
These differences emphasise the importance of establishing refer-
ence intervals for different populations, and the interest of carrying
out comparisons.
We believe that our reference intervals can serve as useful stan-
dards for bone turnover in the adult population in Australia.
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